SCHEMBL1699149

SCHEMBL1699149

O=C(/C=C/c1ccccc1)N(c1ccccc1)C1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 12/20 1.00
ALDH1A1 P00352 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
HTR2A P28223 1/20 0.61
HTR2C P28335 1/20 0.61
HTR2B P41595 1/20 0.61
SIGMAR1 Q99720 1/20 0.61
LMNA P02545 1/20 0.56
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
MITF O75030 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
PAX8 Q06710 1/20 0.55
HTT P42858 1/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA4 P22748 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699151 1.00 TRPM8 (1.00) TRPM8ALDH1A1SMN1; SMN2HTR2AHTR2C
SCHEMBL22100712 0.91 TRPM8 (0.82) TRPM8ALDH1A1SMN1; SMN2HTR2AHTR2C
SCHEMBL10270947 0.87 TRPM8 (1.00) TRPM8ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL10270350 0.86 TRPM8 (0.74) TRPM8ALDH1A1SMN1; SMN2HTR2AHTR2C
SCHEMBL22074358 0.86 TRPM8 (0.74) TRPM8ALDH1A1SMN1; SMN2HTR2AHTR2C
SCHEMBL22100754 0.83 TRPM8 (0.73) TRPM8ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL20250760 0.83 TRPM8 (0.71) TRPM8ALDH1A1SMN1; SMN2HTR2AHTR2C
SCHEMBL10575004 0.82 TRPM8 (0.69) TRPM8ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL13471440 0.82 TRPM8 (1.00) TRPM8SMN1; SMN2NPC1RAB9A
SCHEMBL10270345 0.81 TRPM8 (1.00) TRPM8ALDH1A1SMN1; SMN2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3663366-B1 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2025-01-08 EP disclosed
CN-111053775-B Physiologically cool active ingredient and use of substances containing such active ingredient 西姆莱斯股份公司 2023-08-18 CN disclosed
EP-2501761-B1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2020-06-17 EP disclosed
EP-2501761-B1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2020-06-17 EP disclosed
EP-3663366-A2 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS Symrise AG (DE) 2020-06-10 EP disclosed
EP-3663366-A2 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS Symrise AG (DE) 2020-06-10 EP disclosed
US-10584134-B2 Use of physiological cooling active ingredients, and agents containing such active ingredients SYMRISE AG (DE) 2020-03-10 US disclosed
US-20180093997-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2018-04-05 US disclosed
US-20180093997-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2018-04-05 US disclosed
US-20180093997-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2018-04-05 US disclosed
US-8927605-B2 Use of physiological cooling active ingredients, and agents containing such active ingredients SYMRISE AG (DE) 2015-01-06 US disclosed
US-8927605-B2 Use of physiological cooling active ingredients, and agents containing such active ingredients SYMRISE AG (DE) 2015-01-06 US disclosed
US-20120263659-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS BASF SE (DE) 2012-10-18 US disclosed
US-20120263659-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS BASF SE (DE) 2012-10-18 US disclosed
US-20120263659-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS BASF SE (DE) 2012-10-18 US disclosed
EP-2501761-A2 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS Symrise AG (DE) 2012-09-26 EP disclosed
WO-2011061330-A9 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2012-01-05 WO disclosed
WO-2011061330-A9 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2012-01-05 WO disclosed
WO-2011061330-A2 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2011-05-26 WO disclosed
WO-2011061330-A2 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584134-B2 Use of physiological cooling active ingredients, and agents containing such active ingredients TRPM8, TRPM7, TRPM2 TRPM8 1/4885ALDH1A1 2466/4885SMN1; SMN2 4426/4885
US-20180093997-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS TRPM8, TRPM7, TRPM2 TRPM8 1/4885ALDH1A1 2466/4885SMN1; SMN2 4426/4885
US-20120263659-A1 USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS TRPM8, TRPM7, TRPM2 TRPM8 1/4885ALDH1A1 2466/4885SMN1; SMN2 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.